The mission of the Michigan Cancer Research Consortium (MCRC) is to improve the oncologic health of the communities served by assuring patient access to and participation in state-of-the-art clinical trials and cancer prevention and control activities while contributing to knowledge development in the field of oncology care. The MCRC represents a proven resource with significant potential to serve the objectives of the National Cancer Institute's CCOP program. First funded in 1994 as a single component CCOP, it is now comprised of nine health systems and 120+ investigators from 35+ practices, covering the southeast quadrant of Michigan. Annual accrual exceeds 500+ credits to cancer treatment and prevention/control trials. There are currently 2,492 patients in follow-up. This grant application encompasses and articulates an ever-expanding vision for the Michigan Cancer Research Consortium. Support of and participation in NCI efforts toTevamp the clinical trials network in order to expand translational research and facilitate collaborative team science will be vital to MCRC's future. During the previous grant cycle, the MCRC proved a leader in the development of a web-based program for clinical trials administration, patient scheduling, and investigational drug inventory management. Of importance during this upcoming grant cycle will be the MCRC's continued focus on utilization of technology to maximize efficiencies in access, screening and recruitment to clinical trials. Continuous improvement in efficiencies include further centralization of CCOP administrative activities, e.g., implementation of central hiring and training. The MCRC has systems and relationships in place to foster increases in accrual to both treatment and prevention trials. It is ideally positioned to expand minority participation via a network of community organizations throughout its service area. Over a short 12-year period, the MCRC has become a leader in the NCI's CCOP program. The MCRC investigators and research staff are committed to its ongoing growth and achievement of objectives for the betterment of community cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA063848-17
Application #
7858100
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Whitman, Cynthia B
Project Start
1994-08-05
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
17
Fiscal Year
2010
Total Cost
$1,515,501
Indirect Cost
Name
Saint Joseph Mercy Health System
Department
Type
DUNS #
807606249
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Hubbard, Joleen M; Mahoney, Michelle R; Loui, William S et al. (2017) Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 12:201-209
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Crozier, Jennifer A; Advani, Pooja P; LaPlant, Betsy et al. (2016) N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy. Clin Breast Cancer 16:23-30
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64

Showing the most recent 10 out of 150 publications